Kerala HC Stays Coercive Action Under New Digital Media Guidelines

Chennai : The Kerala High Court, on Wednesday, granted a stay on the operation of Part III of the Information Technology (Intermediary Guidelines and Digital Media Ethics Code) Rules, 2021 (the “Intermediary Rules 2021”) to LiveLaw Media Pvt. Ltd, in response to a writ petition filed by the legal news website.

LiveLaw’s petition was filed on March 9, 2021, and came up for hearing on Wednesday (March 10). LiveLaw’s arguments were centred on the fact that the parent statute, the IT Act, 2000, under which the Intermediary Rules 2021 have been purported to be made, don’t allow the regulation of digital news media.

The IT act applies to intermediaries. Hence, digital news media portals don’t fall under the ambit of the act. However, the new rules seek to regulate the content on news portals as well as video-streaming or OTT platforms by mandating a three-tier oversight mechanism.

At the first level, any person could write a complaint to a news website’s grievance officer about a particular piece of content on the website. The grievance officer would have to acknowledge the receipt of the complaint within 24 hours and communicate his/her decision to the complainant within 15 days. If the news website chooses to not remove the piece of content, then a self-regulating body appointed subject to the central government’s approval will judge the suitability of such content, and on the third level, the central government itself shall decide whether to remove such content.

The petitioner (LiveLaw) claimed that these rules have been framed despite the government not enjoying such powers to regulate news media under the IT Act.

On March 9, the Foundation for Independent Journalism (FIJ), which runs the news website The Wire (thewire.in), along with the editor of The News Minute (thenewsminute.com), also challenged the new guidelines in a writ petition filed in the Delhi High Court. While LiveLaw’s petition challenged all aspects of the new rules, including those applying to social media and OTT platforms, FIJ’s petition only challenged the section of the rules, specifically Part III, which applies to digital news media.

The Delhi HC has issued a notice on the matter, giving the Union of Indian time to file a counter-affidavit. The next hearing on the matter in the Delhi HC will be held on April 16, 2021.

  • Related Posts

    24-year-old woman dies during surgery; Five UP doctors booked for negligence

    Ballia: In an alleged case of medical negligence, a case has been registered against five doctors at a private hospital in Ballia, Uttar Pradesh, following the death of a 24-year-old…

    Extortion, Fake Medicines: The Fall Of Surat’s Yoga Guru

    The yoga guru, who was arrested last week, misled people in the name of faith and Ayurveda, said investigators. Surat: Just days after Ahmedabad cops dismantled a massive fake currency…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    24-year-old woman dies during surgery; Five UP doctors booked for negligence

    24-year-old woman dies during surgery; Five UP doctors booked for negligence

    Extortion, Fake Medicines: The Fall Of Surat’s Yoga Guru

    Extortion, Fake Medicines: The Fall Of Surat’s Yoga Guru

    Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025

    Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025

    Ship of Domestic Medical Device Industry flounders, thanks to Israel-Iran War

    Ship of Domestic Medical Device Industry flounders, thanks to Israel-Iran War

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    India’s drug body flags 90 unapproved FDC medicines, states told to take action

    India’s drug body flags 90 unapproved FDC medicines, states told to take action